Prospera Lung Transplant Assessment – the next generation
- A single blood test to assess all transplant rejection types
- The blood sample contains a mixture of donor DNA (shed from the donor organ) and patient DNA
- Prospera differentiates between donor DNA and patient DNA using differences in single-nucleotide polymorphisms
- Prospera reports the percentage of dd-cfDNA in the patient’s blood, a predictor of active rejection
Experts in cell-free DNA
Optimized for transplant
- Developed by Natera, a leader in cfDNA with a trusted legacy in fetal monitoring, oncology and organ health
- Demonstrated in over 3 million tests1
- Utilizes over 13,000 pan-ethnic SNPs and advanced bioinformatics2
- Optimized to be the most precise cfDNA tool for early, clinically meaningful rejection assessment.3,4
Precision optimized for enhanced performance
Reduce the number of surveillance biopsies by monitoring with Prospera Lung
A noninvasive surveillance test that allows you to determine when a biopsy should be performed on a clinically stable patient
Prospera Lung is an intuitive biomarker for allograft injury with excellent performance
Better science for better care
Easy-to-use with a single blood draw that requires no special processing
Patients First, Partners Always
Natera’s suite of solutions allows for streamlined process integration for your center
A complete, secure bi-directional data and workflow interface with Epic and Cerner systems
- Allows for easy ordering and delivery of results
A concierge team of clinical experts including a medical science liaison, nurse coordinator, & patient coordinator to help patients stay updated on blood draws, compliance plans and results.
Financial Support Program
- Natera welcomes all insurances, and our goal is to make the process easy and transparent for patients
- In the rare event your patient has financial responsibility, Natera offers flexible financial assistance programs and will work closely with your patient to ensure there is no hardship on them or their family.
Find out more about Prospera for lung transplant recipients
1Natera Inc. Natera validation data: manuscript submitted. Data on file.
2Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2018 (per published article);8(1):19 doi:10.3390/jcm8010019
3Altug Y, Liang N, Ram R, et al. Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients. Transplantation. 2019;103(12):2657-2665. doi:10.1097/TP.0000000000002665
4Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18(6):890-902 doi:10.1016/j. jmoldx.2016.07.0038.
5U.S. Department of Health & Human Services: Health Resources and Services Administration. Scientific Registry of Transplant Recipients (SRTR): Organ Procurement and Transplantation Network (OPTN)/SRTR 2019 Annual Data Report: Heart. Available at: https://srtr.transplant.hrsa.gov/annual_reports/2019/Heart. aspx#HR_tx_adult_inc_AR_age_b64. Accessed June 1, 2021.
6Toyoda Y, Toyoda Y. Heart-lung transplantation: adult indications and outcomes. J Thorac Dis. 2014;6(8):1138-1142. doi:10.3978/j.issn.2072-1439.2014.06.01